4-Methyl-6-(2-methyl-1-oxoisoquinolin-4-yl)-1,4-benzoxazin-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 4-Methyl-6-(2-methyl-1-oxoisoquinolin-4-yl)-1,4-benzoxazin-3-one
• 化学式: C₁₉H₁₆N₂O₃
• 分子量: 320.3
• InChiKey: JLGYTQNBVCXSHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Bromodomain inhibitors
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US10807982B2

  公开（公告）日：2020-10-20

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

  本发明涉及取代的杂环衍生物化合物、包含所述化合物的组合物，以及所述化合物和组合物通过抑制溴域介导的对蛋白质（如组蛋白）乙酰赖氨酸区的识别来进行表观遗传调控的用途。所述组合物和方法可用于治疗癌症和肿瘤性疾病。
• BROMODOMAIN INHIBITOR
  申请人：Celgene Quanticel Research, Inc.

  公开号：EP3283077A2

  公开（公告）日：2018-02-21
• BROMODOMAIN INHIBITORS
  申请人：Celgene Quanticel Research, Inc.

  公开号：EP3283077B1

  公开（公告）日：2021-03-10
• US9908885B2
  申请人：——

  公开号：US9908885B2

  公开（公告）日：2018-03-06
• [EN] BROMODOMAIN INHIBITOR<br/>[FR] INHIBITEUR DE BROMODOMAINE
  申请人：CELGENE QUANTICEL RES INC

  公开号：WO2016168682A2

  公开（公告）日：2016-10-20

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.